Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
Year: 2015
Type: article
Source: Blood
Authors: Courtney DiNardo, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, Gail J Roboz, Robert Collins, Ronan T. Swords, Ian W. Flinn, Jessica K Altman, Martin S Tallman, Hagop M. Kantarjian, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone
Institutions: The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, University of Colorado Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University, Massachusetts General Hospital, Weill Cornell Medicine, The University of Texas Southwestern Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Sarah Cannon, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2555424581